Lilly Treatment Impresses in Study

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

An investigational rheumatoid arthritis treatment developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has shown promise in a late-stage trial. Lilly Bio-Medicines President David Ricks says the study is the first to show a daily oral treatment could be superior to traditional injectable treatments in addressing the condition.

Ricks says, if approved, baricitinib "could help change expectations for people living with this debilitating disease."

The company says baricitinib met health improvement scores through 12 and 24 weeks of use, with benefits being maintained through 52 weeks of therapy.

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.